The European Commission (EC) has granted marketing authorisation for Kygevvi (doxecitine and doxribtimine) for the treatment of thymidine kinase 2 deficiency (TK2d).  The approval, making Kygevvi the first and only treatment for TK2d, can now be used to treat paediatric and adult patients with the condition with an age of symptom onset on or before […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!